Studies on Ac-AIP-1 in a TNBS colitis model show suppression of colon IL-10, TGF-β and TSLP and Treg cell accumulation, making the protein a novel therapeutic candidate for inflammatory bowel disease treatment (Ferreira et al., 2017). Here, TGFB1 is linked to colitis.